Compound Comparisons, Research Library

BPC-157 vs TB-500: Comparing Two Research Peptides

Research Use Only Disclaimer: All content on this page is intended strictly for educational and research purposes. The compounds discussed are not approved by the FDA for human use and are not intended to diagnose, treat, cure, or prevent any disease or condition. For in vitro and preclinical research use only.

Overview

BPC-157 and TB-500 are two of the most widely studied synthetic peptides in preclinical tissue repair research. While they are often investigated together — and available as a combined compound — they have distinct molecular origins, mechanisms, and study profiles. This reference compares the two across key research parameters.

Quick Reference

BPC-157TB-500
Full nameBody Protection Compound-157Thymosin Beta-4 (synthetic fragment)
OriginDerived from gastric juice proteinSynthetic fragment of Thymosin Beta-4
Amino acids1543
Molecular weight1,419.5 g/mol4,963 g/mol
Primary research focusGI, tendon, neuroprotectionMuscle, cardiac, systemic repair
SolubilityWater-solubleWater-soluble

Mechanism of Action

BPC-157

Research suggests BPC-157 operates primarily through modulation of the nitric oxide (NO) system and upregulation of growth hormone receptors at injury sites. Studies have also documented interaction with dopaminergic and serotonergic signaling pathways.

TB-500

TB-500 is a synthetic analogue of the active region of Thymosin Beta-4. Its primary investigated mechanism involves actin regulation — specifically, sequestering G-actin to modulate cell migration and angiogenesis. Studies have highlighted its role in promoting endothelial and keratinocyte migration.

Research Applications

Where BPC-157 Has Been More Studied

  • Gastrointestinal injury and ulceration models
  • Tendon-to-bone healing
  • Traumatic brain injury models
  • Drug-induced organ damage models

Where TB-500 Has Been More Studied

  • Cardiac muscle repair
  • Systemic wound healing
  • Corneal tissue repair
  • Hair follicle activation models

Combined Research

Several research groups have investigated BPC-157 and TB-500 in combination, with the hypothesis that their complementary mechanisms — local (BPC-157) vs systemic (TB-500) repair signaling — may produce additive effects in musculoskeletal repair models. Combined formulations are available for researchers wishing to study both compounds simultaneously.

Research Use Only Disclaimer: All content on this page is intended strictly for educational and research purposes. The compounds discussed are not approved by the FDA for human use and are not intended to diagnose, treat, cure, or prevent any disease or condition. For in vitro and preclinical research use only.

Leave a Reply

Your email address will not be published. Required fields are marked *